Castle supports educational programs, initiatives for esophageal cancer

Castle Biosciences (CSTL) is supporting key educational programs and initiatives throughout the month of April in recognition of Esophageal Cancer Awareness Month. The Company is collaborating with the Esophageal Cancer Action Network, ECAN, the American Foregut Society, AFS, and The Gut Doctor Podcast to promote esophageal cancer prevention, education and advocacy. “As esophageal cancer is often diagnosed in its late stages, its five-year survival rate remains alarmingly low at around 20%,”1 said Emmanuel Gorospe, M.D., board-certified gastroenterologist and medical director, gastroenterology, of Castle Biosciences. “This makes early detection and prevention critical. Through our collaboration with advocacy groups and the gastrointestinal community, we are committed to raising awareness of esophageal cancer risk factors and providing meaningful support to patients and healthcare professionals alike.”